High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance | Zendy

Samo Jeverica | Zendy; Daniel Golparian | Zendy; Brian L. Hanzelka | Zendy; A. J. Fowlie | Zendy; Maria Letícia de Miranda Mati | Zendy; Magnus Unemo | Zendy

Open Access

High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance

Author(s) -

Samo Jeverica,

Daniel Golparian,

Brian L. Hanzelka,

A. J. Fowlie,

Maria Letícia de Miranda Mati,

Magnus Unemo

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku073

Subject(s) - neisseria gonorrhoeae , ciprofloxacin , microbiology and biotechnology , etest , antimicrobial , topoisomerase iv , agar dilution , dna gyrase , minimum inhibitory concentration , multiple drug resistance , antibiotic resistance , biology , drug resistance , antibiotics , escherichia coli , biochemistry , gene

Clinical resistance to the currently recommended extended-spectrum cephalosporins (ESCs), the last remaining options for empirical antimicrobial monotherapy of gonorrhoea globally, has been reported. New antimicrobials are essential to avoid the emergence of untreatable gonorrhoea. We have investigated the in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (Vertex aminobenzimidazole VT12-008911), compared with antimicrobials currently or previously recommended for gonorrhoea treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research